Bioresorbable Scaffold Technology: The Yet Unfulfilled Promise of Becoming the Workhorse Stent in the Cardiac Catherization Laboratory

Overview

Journal Egypt Heart J

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2018 Dec 29

PMID 30591764

Authors

Wael Elabbassi

Mohammed Andaleeb Chowdhury

Robert Hatala

Affiliations

Soon will be listed here.

References

Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S . Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102(4):399-404. DOI: 10.1161/01.cir.102.4.399. View

Sousa J, Costa M, Abizaid A, Rensing B, Abizaid A, Tanajura L . Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104(17):2007-11. DOI: 10.1161/hc4201.098056. View

Morice M, Serruys P, Sousa J, Fajadet J, Ban Hayashi E, Perin M . A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773-80. DOI: 10.1056/NEJMoa012843. View

Kimura T, Abe K, Shizuta S, Odashiro K, Yoshida Y, Sakai K . Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002; 105(25):2986-91. DOI: 10.1161/01.cir.0000019743.11941.3b. View

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C . Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004; 109(18):2168-71. DOI: 10.1161/01.CIR.0000128850.84227.FD. View

Ormiston J, Webster M, Armstrong G . First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2006; 69(1):128-31. DOI: 10.1002/ccd.20895. View

Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C . Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369(9562):667-78. DOI: 10.1016/S0140-6736(07)60314-6. View

Tanimoto S, Serruys P, Thuesen L, Dudek D, De Bruyne B, Chevalier B . Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007; 70(4):515-23. DOI: 10.1002/ccd.21136. View

Erbel R, Di Mario C, Bartunek J, Bonnier J, De Bruyne B, Eberli F . Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007; 369(9576):1869-1875. DOI: 10.1016/S0140-6736(07)60853-8. View

10.

Ormiston J, Serruys P, Regar E, Dudek D, Thuesen L, Webster M . A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371(9616):899-907. DOI: 10.1016/S0140-6736(08)60415-8. View

11.

Tanimoto S, Bruining N, van Domburg R, Rotger D, Radeva P, Ligthart J . Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol. 2008; 52(20):1616-20. DOI: 10.1016/j.jacc.2008.08.024. View

12.

Garcia-Garcia H, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L . Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB.... EuroIntervention. 2009; 4(4):443-8. DOI: 10.4244/eijv4i4a77. View

13.

Serruys P, Ormiston J, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia H . A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667):897-910. DOI: 10.1016/S0140-6736(09)60325-1. View

14.

Serruys P, Ong A, Piek J, Neumann F, van der Giessen W, Wiemer M . A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2009; 1(1):58-65. View

15.

Tsuchida K, Piek J, Neumann F, van der Giessen W, Wiemer M, Zeiher A . One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention. 2009; 1(3):266-72. View

16.

Garg S, Serruys P . Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol. 2009; 57(5):537-65. View

17.

Serruys P, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice M . 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010; 55(11):1093-101. DOI: 10.1016/j.jacc.2009.11.049. View

18.

Okamura T, Garg S, Gutierrez-Chico J, Shin E, Onuma Y, Garcia-Garcia H . In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention. 2010; 5(8):932-8. View

19.

Okamura T, Onuma Y, Garcia-Garcia H, Regar E, Wykrzykowska J, Koolen J . 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. JACC Cardiovasc Interv. 2010; 3(8):836-44. DOI: 10.1016/j.jcin.2010.05.011. View

20.

Onuma Y, Serruys P, Ormiston J, Regar E, Webster M, Thuesen L . Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010; 6(4):447-53. DOI: 10.4244/EIJ30V6I4A76. View